First Hawaiian, Inc. (FHB) Analysts See $0.48 EPS; Islet Sciences (ONCE)’s Sentiment Is 1.43

April 18, 2018 - By David King

Spark Therapeutics, Inc. (NASDAQ:ONCE) Logo

Analysts expect First Hawaiian, Inc. (NASDAQ:FHB) to report $0.48 EPS on April, 26 after the close.They anticipate $0.07 EPS change or 17.07% from last quarter’s $0.41 EPS. FHB’s profit would be $67.02M giving it 14.40 P/E if the $0.48 EPS is correct. After having $0.42 EPS previously, First Hawaiian, Inc.’s analysts see 14.29% EPS growth. The stock decreased 1.18% or $0.33 during the last trading session, reaching $27.64. About 183,254 shares traded. First Hawaiian, Inc. (NASDAQ:FHB) has declined 4.70% since April 18, 2017 and is downtrending. It has underperformed by 16.25% the S&P500.

Islet Sciences Inc (ONCE) investors sentiment decreased to 1.43 in 2017 Q4. It’s down -1.51, from 2.94 in 2017Q3. The ratio dropped, as 96 investment managers increased and opened new equity positions, while 67 reduced and sold positions in Islet Sciences Inc. The investment managers in our database now have: 35.76 million shares, up from 33.64 million shares in 2017Q3. Also, the number of investment managers holding Islet Sciences Inc in top ten equity positions decreased from 1 to 0 for a decrease of 1. Sold All: 41 Reduced: 26 Increased: 55 New Position: 41.

Among 10 analysts covering First Hawaiian (NASDAQ:FHB), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. First Hawaiian had 16 analyst reports since August 11, 2016 according to SRatingsIntel. Credit Suisse initiated the shares of FHB in report on Monday, August 29 with “Outperform” rating. UBS maintained it with “Neutral” rating and $29 target in Monday, July 31 report. The firm has “Overweight” rating by JP Morgan given on Monday, August 29. The firm has “Neutral” rating given on Monday, August 29 by UBS. Keefe Bruyette & Woods initiated the stock with “Market Perform” rating in Monday, August 29 report. Barclays Capital initiated First Hawaiian, Inc. (NASDAQ:FHB) on Monday, August 29 with “Overweight” rating. UBS maintained the shares of FHB in report on Friday, October 27 with “Neutral” rating. Compass Point initiated First Hawaiian, Inc. (NASDAQ:FHB) on Thursday, August 11 with “Buy” rating. The firm has “Neutral” rating by Citigroup given on Monday, August 29. The stock of First Hawaiian, Inc. (NASDAQ:FHB) has “Overweight” rating given on Wednesday, October 11 by Barclays Capital.

First Hawaiian, Inc. operates as a bank holding firm for First Hawaiian Bank that provides banking services to consumer and commercial clients in the United States. The company has market cap of $3.86 billion. The firm operates through Retail Banking and Commercial Banking divisions. It has a 21 P/E ratio. It accepts various deposit products, such as checking and savings accounts, and time deposit accounts.

Ratings analysis reveals 100% of Spark Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Spark Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $73.0 while the high is $85.0. The stock’s average target of $79 is -2.09% below today’s ($80.69) share price. ONCE was included in 2 notes of analysts from September 2, 2016. The rating was initiated by Stifel Nicolaus on Friday, September 2 with “Buy”. The rating was initiated by Leerink Swann on Thursday, February 9 with “Outperform”.

Analysts await Spark Therapeutics, Inc. (NASDAQ:ONCE) to report earnings on May, 8. They expect $-0.45 EPS, up 73.53% or $1.25 from last year’s $-1.7 per share. After $-1.73 actual EPS reported by Spark Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -73.99% EPS growth.

The stock increased 3.73% or $2.9 during the last trading session, reaching $80.69. About 536,982 shares traded. Spark Therapeutics, Inc. (ONCE) has risen 21.52% since April 18, 2017 and is uptrending. It has outperformed by 9.97% the S&P500.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $3.00 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

Great Point Partners Llc holds 3.61% of its portfolio in Spark Therapeutics, Inc. for 410,900 shares. Rock Springs Capital Management Lp owns 615,000 shares or 1.43% of their US portfolio. Moreover, Eventide Asset Management Llc has 0.87% invested in the company for 324,000 shares. The New York-based Baker Bros. Advisors Lp has invested 0.62% in the stock. Sphera Funds Management Ltd., a Israel-based fund reported 100,000 shares.

First Hawaiian, Inc. (NASDAQ:FHB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.